AVE vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how AVE (AVE) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees AVE as the less overvalued of the two: AVE trades at A$0.02 versus a fair value of A$0.02 (-18%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
AVE
AVE.AU · AUD · Health Care
-18%
upside to fair value
overvalued
PriceA$0.02
Fair ValueA$0.02
Quality42/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
AVEVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
46.30×P/S (TTM)10.06×
36.74×P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
Profitability
0%Net margin36%
-199%Operating margin38%
-183%Return on equity24%
-41%Return on assets12%
Growth
-17%Revenue growth (YoY)8%
3.1%Avg. growth/yr (3Y)10.6%
26.3%Avg. growth/yr (5Y)14.2%
Balance & size
—Debt / equity0.03×
$57MMarket cap$123B
mixedGrowth qualityhealthy
Vertex Pharmaceuticals leads: 1 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
AVEof which business quality 48 · market factors 75Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
4
72
Quality GrowthAre margins and returns improving?
38
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
67
58
Low VolatilityCalm price path (market factor)
26
86
MomentumPrice trend over the last 3–12 months (market factor)
100
54
52W MomentumDistance to the 52-week high (market factor)
89
59
Net IssuanceBuybacks instead of dilution
17
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
AVE
DCF ModelsA$0.01
Dividend DiscountA$0.01
Growth DCFA$0.01
4 of 4 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
18 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
AVE · Health Care
Quality score42 · below median
Fair value upside-18% · above median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-44% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees AVE as the less overvalued of the two: AVE trades at A$0.02 versus a fair value of A$0.02 (-18%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
